Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 2 | 3 |
| 2009 | 2 | 4 | 6 |
| 2010 | 3 | 6 | 9 |
| 2011 | 6 | 2 | 8 |
| 2012 | 4 | 0 | 4 |
| 2013 | 3 | 5 | 8 |
| 2014 | 6 | 6 | 12 |
| 2015 | 8 | 3 | 11 |
| 2016 | 2 | 3 | 5 |
| 2017 | 5 | 0 | 5 |
| 2018 | 8 | 1 | 9 |
| 2019 | 7 | 4 | 11 |
| 2020 | 4 | 4 | 8 |
| 2021 | 2 | 4 | 6 |
| 2022 | 1 | 4 | 5 |
| 2023 | 0 | 3 | 3 |
| 2024 | 2 | 2 | 4 |
| 2025 | 5 | 1 | 6 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E. JCO Precis Oncol. 2026 Feb; 10:e2500612.
-
Discovery of VU6083859, a TAOK1 Selective Inhibitor, and VU6080195, a pan-TAOK Activator. ACS Chem Neurosci. 2026 Feb 04; 17(3):624-634.
-
Efficacy and safety of BRAF-MEK dual inhibition in BRAF-V600E mutated papillary craniopharyngioma: a systematic review. J Neurooncol. 2025 Oct 30; 176(1):58.
-
Pregnancy-Related Adverse Events with Tyrosine Kinase Inhibitor Use in Chronic Myeloid Leukemia: A FAERS Pharmacovigilance Analysis (2001-2024). Clin Lymphoma Myeloma Leuk. 2026 Feb; 26(2):e229-e232.
-
Sustained response to larotrectinib in a pediatric patient with recurrent STRN3::NTRK2 fusion-positive pilocytic astrocytoma. CNS Oncol. 2025 Dec; 14(1):2558455.
-
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P. JCO Precis Oncol. 2025 Aug; 9:e2500265.
-
Focal adhesion kinase (FAK): emerging target for drug-resistant malignant tumors. Mol Biol Rep. 2025 Feb 20; 52(1):248.
-
Prognostic value of survival in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors: Value of SUVmax or value of other factor? Clin Ter. 2025 Jan-Feb; 176(1):52-59.
-
Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein. J Med Chem. 2025 Jan 09; 68(1):81-94.
-
Quantitative Top-down Proteomics Revealed Kinase Inhibitor-Induced Proteoform-Level Changes in Cancer Cells. J Proteome Res. 2025 Jan 03; 24(1):303-314.